(Q40510477)

21 September 2017

title

Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein (English)

1 reference

21 September 2017

0 references

0 references

2

Maribel Acosta

1 reference

21 September 2017

Javier Mota

1

1 reference

21 September 2017

Rocio Argotte

3

1 reference

21 September 2017

Raymunda Figueroa

4

1 reference

21 September 2017

Armando Méndez

5

1 reference

21 September 2017

Celso Ramos

6

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

21 September 2017

1 reference

21 September 2017

volume

23

1 reference

21 September 2017

issue

26

1 reference

21 September 2017

page(s)

3469-3476

1 reference

Dengue: the risk to developed and developing countries

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

7 January 2021

Yellow fever vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Japanese encephalitis and dengue vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Current status of flavivirus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Traditional and novel approaches to flavivirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Development of new vaccines against dengue fever and Japanese encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

The future of dengue vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Live attenuated tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Defective adenoviruses as novel vaccines for the Flaviviridae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Production of anti-dengue NS1 monoclonal antibodies by DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

A ligand-binding pocket in the dengue virus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Host cell selection of Murray Valley encephalitis virus variants altered at an RGD sequence in the envelope protein and in mouse virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

A single nucleotide change in the E protein gene of dengue virus 2 Mexican strain affects neurovirulence in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Molecular evolution and distribution of dengue viruses type 1 and 2 in nature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

7 January 2021

Dengue virus structural differences that correlate with pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

7 January 2021

Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

7 January 2021

Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.028

7 January 2021

10.1016/J.VACCINE.2004.12.028

Identifiers

DOI

1 reference

21 September 2017

1 reference